- Home
- SGMT vs DMAC Comparison
SGMT vs DMAC Comparison
Compare SGMT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- DMAC
- Stock Information
- Founded
- SGMT 2006
- DMAC 2000
- Country
- SGMT United States
- DMAC United States
- Employees
- SGMT N/A
- DMAC N/A
- Industry
- SGMT
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- DMAC Health Care
- Exchange
- SGMT Nasdaq
- DMAC Nasdaq
- Market Cap
- SGMT 269.2M
- DMAC 260.0M
- IPO Year
- SGMT 2023
- DMAC N/A
- Fundamental
- Price
- SGMT $8.71
- DMAC $6.01
- Analyst Decision
- SGMT Strong Buy
- DMAC Strong Buy
- Analyst Count
- SGMT 8
- DMAC 4
- Target Price
- SGMT $27.25
- DMAC $10.75
- AVG Volume (30 Days)
- SGMT 722.5K
- DMAC 445.6K
- Earning Date
- SGMT 08-13-2025
- DMAC 08-12-2025
- Dividend Yield
- SGMT N/A
- DMAC N/A
- EPS Growth
- SGMT N/A
- DMAC N/A
- EPS
- SGMT N/A
- DMAC N/A
- Revenue
- SGMT N/A
- DMAC N/A
- Revenue This Year
- SGMT N/A
- DMAC N/A
- Revenue Next Year
- SGMT N/A
- DMAC N/A
- P/E Ratio
- SGMT N/A
- DMAC N/A
- Revenue Growth
- SGMT N/A
- DMAC N/A
- 52 Week Low
- SGMT $1.73
- DMAC $3.19
- 52 Week High
- SGMT $11.41
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SGMT 55.77
- DMAC 71.96
- Support Level
- SGMT $8.62
- DMAC $4.39
- Resistance Level
- SGMT $10.06
- DMAC $6.40
- Average True Range (ATR)
- SGMT 0.70
- DMAC 0.47
- MACD
- SGMT -0.05
- DMAC 0.13
- Stochastic Oscillator
- SGMT 58.06
- DMAC 83.65
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.